关于大麻素类药物作为镇痛药的临床前科学：概述。

Preclinical science regarding cannabinoids as analgesics: an overview.

机构信息

Pain Management Unit, Queen Elizabeth II Health Sciences Centre, Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia.

出版信息

Pain Res Manag. 2005 Autumn;10 Suppl A:7A-14A. doi: 10.1155/2005/169093.

DOI:10.1155/2005/169093

PMID:16237476

Abstract

Modern pharmacology of cannabinoids began in 1964 with the isolation and partial synthesis of delta-9-tetrahydrocannabinol, the main psycho-active agent in herbal cannabis. Since then, potent antinociceptive and antihyperalgesic effects of cannabinoid agonists in animal models of acute and chronic pain; the presence of cannabinoid receptors in pain-processing areas of the brain, spinal cord and periphery; and evidence supporting endogenous modulation of pain systems by cannabinoids has provided support that cannabinoids exhibit significant potential as analgesics. The present article presents an overview of the preclinical science.

摘要

大麻素的现代药理学始于 1964 年，当时分离并部分合成了 δ-9-四氢大麻酚，这是草药大麻中主要的精神活性物质。从那时起，大麻素激动剂在急性和慢性疼痛的动物模型中具有强大的镇痛和抗痛觉过敏作用；在大脑、脊髓和外周的疼痛处理区域存在大麻素受体；并且有证据支持内源性大麻素系统对疼痛系统的调节，这些都为大麻素作为镇痛药具有显著的潜力提供了支持。本文对临床前科学进行了概述。